國家衛生研究院 NHRI:Item 3990099045/10973

NHRI > Institute of Biomedical Engineering and Nanomedicine > Dong-Ming Huang > Periodical Articles > Item 3990099045/10973

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10973

Title:	Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson's disease
Authors:	Chung, TH;Hsu, SC;Wu, SH;Hsiao, JK;Lin, CP;Yao, M;Huang, DM
Contributors:	Institute of Biomedical Engineering and Nanomedicine
Abstract:	Parkinson's disease (PD) is a prevalent neurodegenerative disease characterized by the loss of dopaminergic (DA) neurons. With their migration capacity toward the sites of diseased DA neurons in the PD brain, mesenchymal stem cells (MSCs) have the potential to differentiate to DA neurons for the replacement of damaged neurons and to secrete neurotrophic factors for the protection and regeneration of diseased DA neurons; therefore MSCs show promise for the treatment of PD. In this study, for the first time, we demonstrate that dextran-coated iron oxide nanoparticles (Dex-IO NPs) can improve the therapeutic efficacy of human MSCs (hMSCs) in a mouse model of PD induced by a local injection of 6-hydroxydopamine (6-OHDA). In situ examinations not only show that Dex-IO NPs can improve the rescue effect of hMSCs on the loss of host DA neurons but also demonstrate that Dex-IO NPs can promote the migration capacity of hMSCs toward lesioned DA neurons and induce the differentiation of hMSCs to DA-like neurons at the diseased sites. We prove that in vitro Dex-IO NPs can enhance the migration of hMSCs toward 6-OHDA-damaged SH-SY5Y-derived DA-like cells, induce hMSCs to differentiate to DA-like neurons in the conditioned media derived from 6-OHDA-damaged SH-SY5Y-derived DA-like cells and promote the protection/regeneration effects of hMSCs on 6-OHDA-damaged SH-SY5Y-derived DA-like cells. We confirm the potential of MSCs for cell-based therapy for PD. Dex-IO NPs can be used as a tool to accelerate and optimize MSC therapeutics for PD applicable clinically.
Date:	2018-02
Relation:	Nanoscale. 2018 Feb;10(6):2998-3007.
Link to:	http://dx.doi.org/10.1039/c7nr06976f
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2040-3364&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000424694400038
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85041807476
Appears in Collections:	[Dong-Ming Huang] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB29372743.pdf		3157Kb	Adobe PDF	491	View/Open

Loading...